Moderate to Severe Plaque Psoriasis Epidemiology Forecast 2025-2034

The moderate to severe plaque psoriasis epidemiological forecast suggests that the prevalence of moderate to severe plaque psoriasis is influenced by genetic predisposition and environmental factors, including sun exposure, climate, and air pollution. The National Psoriasis Foundation states that moderate psoriasis affects between 3% and 10% of the body, whereas severe psoriasis impacts more than 10% of the body. Further, a 2021 study published in the International Journal of Research in Dermatology indicates that around 20% of people with plaque psoriasis experience moderate to severe forms of the disease.

Moderate to Severe Plaque Psoriasis Epidemiology Forecast Report Coverage

The “Moderate to Severe Plaque Psoriasis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of moderate to severe plaque psoriasis. It projects the future incidence and prevalence rates of moderate to severe plaque psoriasis cases across various populations. The study covers age and type as major determinants of the moderate to severe plaque psoriasis population. The report highlights patterns in the prevalence of moderate to severe plaque psoriasis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on moderate to severe plaque psoriasis epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Moderate to Severe Plaque Psoriasis Understanding: Disease Overview

Moderate to severe plaque psoriasis is a chronic autoimmune skin condition that causes rapid skin cell turnover. It is characterized by thick, red, scaly patches known as plaques. Moderate to severe plaque psoriasis is a more advanced and intense form of plaque psoriasis. In this condition, the plaques are more widespread, thicker, and more inflamed, significantly impacting the patient's quality of life.

Psoriatic arthritis can occur alongside moderate to severe plaque psoriasis, leading to joint pain, stiffness, and damage. Nail changes, such as pitting and discoloration, are also common symptoms. A family history of psoriasis or other autoimmune diseases is reported to increase the risk of developing moderate to severe plaque psoriasis.

Moderate to Severe Plaque Psoriasis Epidemiology Perspective

The moderate to severe plaque psoriasis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for moderate to severe plaque psoriasis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The moderate to severe plaque psoriasis detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per the National Psoriasis Foundation, mild psoriasis involves less than 3% of the body, moderate psoriasis affects between 3% and 10%, and severe psoriasis impacts more than 10% of the body.
• According to a study by Polyzoi, M et al., the prevalence of moderate to severe plaque psoriasis was estimated to be 0.14%. Additionally, the prevalence of psoriatic arthritis was estimated at 0.18%, while the prevalence of both moderate to severe plaque psoriasis and psoriatic arthritis occurring together was 0.02%.
• Plaque psoriasis, including moderate to severe plaque psoriasis, is reported to affect 1% to 2% of the United States population, with variations observed based on race, geography, and environmental factors like sun exposure.
• According to a 2021 study published in the International Journal of Research in Dermatology, approximately 20% of individuals with plaque psoriasis experience moderate to severe forms of the disease, which significantly impacts their quality of life.
• Plaque psoriasis is the most prevalent form of psoriasis, affecting approximately 6.7 million adults. It accounts for about 80% to 90% of all psoriasis cases, according to the Cleveland Clinic.

Country-wise Moderate to Severe Plaque Psoriasis Epidemiology Segment

The moderate to severe plaque psoriasis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of moderate to severe plaque psoriasis varies significantly between countries due to differences in factors such as environmental factors (including sun exposure, climate, and air pollution), genetics, lifestyle patterns (like diet, stress levels, smoking, and alcohol consumption), and healthcare access, among others. In the United Kingdom, psoriasis, including moderate to severe plaque psoriasis, affects about 2 in 100 people, as per the National Health Service (NHS).

Moderate to Severe Plaque Psoriasis: Treatment Overview

The treatment plan for moderate to severe plaque psoriasis is based on a combination of therapies aimed at reducing inflammation, slowing skin cell turnover, and addressing symptoms. For localized patches, moderate to severe plaque psoriasis therapeutics such as corticosteroids, vitamin D analogs, and topical retinoids are often used.

Phototherapy with ultraviolet B (UVB) light or PUVA therapy (a combination of psoralen and UVA light) is recommended for more widespread moderate to severe plaque psoriasis cases. Biologic therapies, including TNF inhibitors and IL-23 inhibitors, are also considered effective for patients with moderate to severe psoriasis.

Key Questions Answered

• What are the key findings of moderate to severe plaque psoriasis epidemiology in the 8 major markets?
• What will be the total number of patients with moderate to severe plaque psoriasis across the 8 major markets during the forecast period?
• What was the country-wise moderate to severe plaque psoriasis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of moderate to severe plaque psoriasis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of moderate to severe plaque psoriasis during the forecast period of 2025-2034?
• What are the currently available treatments in the moderate to severe plaque psoriasis market?
• What are the disease risks, signs, symptoms, and unmet needs of moderate to severe plaque psoriasis?

Scope of the Moderate to Severe Plaque Psoriasis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of moderate to severe plaque psoriasis based on several factors.
• The Moderate to Severe Plaque Psoriasis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The moderate to severe plaque psoriasis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.